Prostate cancer remains one of the most prevalent and lethal malignancies affecting men worldwide. The immune microenvironment of tumors — comprising immune cells, signaling molecules, and the extracellular matrix — plays a crucial role in tumorigenesis, progression, and treatment resistance. Epigenetic modifications, particularly RNA methylation, have emerged as key modulators impacting gene expression and immune responses. Notably, N6-methyladenosine (m6A) is the most abundant internal modification on messenger RNA (mRNA), regulating RNA stability, splicing, translation, and degradation.

The research team collected tissue samples from prostate cancer patients undergoing surgical resection. Both tumor tissues and adjacent non-cancerous tissues were subjected to detailed immunohistochemical analyses to detect and quantify the expression of YTHDF1 and IGFBP2. The localization of these proteins was restricted predominantly to the cytoplasm of cancer cells, highlighting their functional relevance at the post-transcriptional level in tumor cells.

Quantitative analysis revealed a marked overexpression of YTHDF1 and IGFBP2 in prostate cancer tissue compared with adjacent normal tissue. Specifically, 69.81% of cancer tissues displayed positive YTHDF1 expression, dramatically higher than 33.96% in non-tumorous tissues. Similarly, IGFBP2 was overexpressed in 62.26% of cancer specimens relative to 28.30% in surrounding tissue. These statistically significant differences (p < 0.01) indicate that m6A regulation is intimately linked with prostate oncogenesis.

Delving deeper into clinical parameters, the researchers correlated YTHDF1 and IGFBP2 expression with established prognostic factors such as tumor-node-metastasis (TNM) stage, Gleason score, and prostate-specific antigen (PSA) levels. Positive expression of both YTHDF1 and IGFBP2 was significantly associated with higher TNM stages (III and IV), elevated Gleason scores, and PSA levels exceeding 15 ng/mL. This strong association suggests that these m6A regulators may actively contribute to tumor aggressiveness and metastatic potential.

From a survival analysis perspective, patients exhibiting elevated YTHDF1 expression had a median survival time of only 35 months, substantially lower than the 44 months observed in patients without YTHDF1 expression. Likewise, the IGFBP2 positive group showed a median survival of 32 months compared to 45 months in negative counterparts. These observations underline the prognostic weight that these m6A regulatory proteins carry, potentially outperforming conventional indicators in predicting patient outcomes.

Statistical modeling employing logistic regression further established that YTHDF1 and IGFBP2, along with TNM stage, Gleason score, and PSA, independently predicted poor prognosis in prostate cancer patients. This independence emphasizes that m6A regulators add novel and non-redundant prognostic value which may facilitate more nuanced and personalized patient management.

Mechanistically, YTHDF1 is known to promote mRNA translation by recognizing m6A modifications, thus modulating the expression of oncogenes or tumor suppressors post-transcriptionally. IGFBP2 modulates insulin-like growth factor signaling pathways implicated in cell proliferation, survival, and migration. Their overexpression in prostate cancer likely disrupts normal cell regulatory networks, fostering a more immunosuppressive and tumorigenic microenvironment.

Importantly, the immune microenvironment itself is a dynamic and critical player in prostate cancer progression. The study’s findings suggest that altered m6A methylation status mediated by YTHDF1 and IGFBP2 may shape immune cell infiltration, cytokine profiles, and overall tumor-immune interactions. This immunomodulatory potential elevates these proteins as promising therapeutic targets, especially in the era of immuno-oncology.

Despite the compelling evidence, the authors caution that translation of these findings into clinical practice necessitates validation in larger cohorts and multi-center studies. The heterogeneity of prostate cancer, diverse treatment regimens, and intricacies of m6A machinery require robust investigation before these biomarkers can be integrated into prognostic algorithms or targeted therapeutics.

In summary, this study positions YTHDF1 and IGFBP2 at the forefront of prostate cancer research, linking m6A RNA methylation regulators to tumor progression and immune microenvironment dynamics. Their independent prognostic value and putative functional roles herald new diagnostic and therapeutic avenues, offering hope for improved survival outcomes in patients suffering from this prevalent malignancy.

As research into m6A epitranscriptomics and immune microenvironment interactions rapidly evolves, the integration of such molecular biomarkers promises to transform the landscape of precision oncology. This study is a crucial step toward unraveling the complex biology underpinning prostate cancer progression and may soon catalyze the development of novel interventions targeting m6A-mediated pathways.

Subject of Research: Prostate cancer; role of m6A RNA methylation regulators YTHDF1 and IGFBP2 in tumor immune microenvironment and prognosis.

Article Title: Influence of m6A regulatory factor related to immune microenvironment on the prognosis of prostate cancer.

Article References:
Zhu, W., Liu, Z., Wang, S. et al. Influence of m6A regulatory factor related to immune microenvironment on the prognosis of prostate cancer. BioMed Eng OnLine 24, 124 (2025). https://doi.org/10.1186/s12938-025-01461-x

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s12938-025-01461-x

Prostate cancer remains one of the most prevalent malignancies among men globally, with significant mortality associated with its progression. Despite advances in early detection and treatment modalities, the emergence of secondary primary malignancies among prostate cancer survivors has become an increasingly vexing clinical problem. Unlike metastases that originate from the primary tumor, SPMs constitute distinct neoplasms developing independently, imposing additional complexity on patient management and adversely affecting outcomes.

Secondary primary malignancies occur in approximately 11 to 22 percent of prostate cancer survivors, a statistic that underscores the urgent need for improved stratification tools. The heterogeneous nature of these subsequent cancers, coupled with their variable latency periods and organ-specific predilections, has historically hampered the ability of clinicians to accurately predict survival trajectories. Addressing this gap, the international team led by Guangzhou Medical University utilized the extensive Surveillance, Epidemiology, and End Results (SEER) database to construct a predictive nomogram that provides personalized survival estimates at 1, 3, and 5 years post-diagnosis of SPMs in prostate cancer patients.

Harnessing data from 6,363 prostate cancer survivors with documented SPMs, the researchers applied rigorous statistical methodologies to identify salient prognosticators. Variables including patient age, marital status, site of the secondary tumor, metastatic stage (M stage), American Joint Committee on Cancer (AJCC) staging, prostate-specific antigen (PSA) levels, and prior prostate cancer surgical history emerged as significant predictors through a combination of least absolute shrinkage and selection operator (LASSO) regression and Cox proportional hazards models. This multivariate approach allowed the distillation of complex clinical data into a practical, interpretable nomogram.

The developed nomogram demonstrated remarkable predictive performance, evidenced by area under the receiver operating characteristic curve (AUC) metrics between 0.84 and 0.87 in both training and validation cohorts. Such robustness notably surpasses the discriminative capacity of conventional AJCC staging alone, suggesting that this model captures dimensions of patient risk previously unaccounted for. Further enhancing its clinical utility, the research team deployed an interactive, web-based calculator, facilitating seamless integration into diverse healthcare settings and empowering clinicians with real-time prognostic insights.

Beyond clinical risk modeling, the study pioneers the application of two-sample Mendelian randomization (TSMR) analysis to interrogate genetic relationships between prostate cancer and ten prevalent SPM types. Mendelian randomization leverages germline genetic variants as instrumental variables to infer potential causal links, circumventing confounding factors endemic to observational studies. The analysis revealed a compelling genetic association specifically between prostate cancer and urothelial carcinoma, including bladder and upper tract cancers, suggesting a shared genetic etiology or molecular pathways predisposing patients to these malignancies.

These genetic insights bear significant translational implications. Understanding the mechanistic underpinnings that connect prostate carcinogenesis and urothelial tumorigenesis opens avenues for targeted surveillance strategies. Patients identified as genetically predisposed to developing secondary urothelial cancers could benefit from intensified monitoring protocols, facilitating earlier detection and intervention, which may ultimately improve survival outcomes.

The amalgamation of clinical variables with genetic evidence embodies the ethos of precision medicine, moving away from one-size-fits-all models toward individualized patient care. By capturing the multifaceted nature of disease progression, the nomogram equips physicians to tailor follow-up intervals, determine appropriate therapeutic intensities, and allocate supportive care resources more effectively. This paradigm shift acknowledges that survival is governed by a constellation of factors extending beyond tumor staging alone.

Lead author Dr. Di Gu emphasizes the dual novelty of the study: “Our approach bridges the critical knowledge gap by coupling advanced prognostic modeling with genetic causality analysis. This fusion not only enriches our understanding of disease dynamics in prostate cancer patients with SPMs but also paves the way for precision oncology practices that can be implemented in routine clinical workflows.”

The online calculator provided by the team represents a significant advance in clinical decision support. By translating statistical models into user-friendly tools, clinicians are empowered to generate personalized survival predictions at the bedside, enhancing patient counseling and facilitating shared decision-making. This accessibility ensures that the benefits of complex analytical techniques are no longer confined to research environments but are actively disseminated across varied clinical settings.

Importantly, the study’s findings advocate for a re-evaluation of current prostate cancer survivorship care paradigms. Incorporating genetic risk factors and individualized prognostication into guidelines could lead to proactive screening for secondary malignancies, particularly urothelial cancers, where shared genetic susceptibility appears pronounced. This targeted vigilance could mitigate the morbidity and mortality associated with late-stage diagnosis of secondary tumors.

While the nomogram and genetic analyses constitute a leap forward, ongoing research is necessitated to validate these findings prospectively and to extend the genetic investigations to additional secondary malignancies. Future studies integrating multi-omics data, environmental exposures, and lifestyle factors may further refine risk stratification and elucidate the pathobiology underpinning SPM development.

In sum, this comprehensive research represents a critical inflection point in managing prostate cancer survivors facing the additional challenge of secondary primary malignancies. By synthesizing robust clinical modeling with pioneering genetic approaches, it offers clinicians potent tools to navigate this complex clinical landscape and underscores the transformative potential of precision oncology to enhance patient survival and quality of life.

Subject of Research: Not applicable

Article Title: Development of a prognostic nomogram and genetic insights for prostate cancer patients with secondary primary malignancies: A SEER retrospective cohort study and Mendelian randomization analysis

News Publication Date: 10-Jul-2025

Web References:
http://dx.doi.org/10.1002/uro2.70017

References:
DOI: 10.1002/uro2.70017

Image Credits: UroPrecision

Keywords: Prostate cancer